PEAK6 Investments’s Sarepta Therapeutics SRPT Stock Holding History

PEAK6 Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,094	Closed	-$576K	–	4557
2023 Q2	$583K	Buy	+5,094	New	+$657K	﹤0.01%	2089
2022 Q3	–	Sell	-5,094	Closed	-$513K	–	6050
2022 Q2	$583K	Buy	+5,094	New	+$375K	﹤0.01%	3654
2021 Q3	–	Sell	-9,160	Closed	-$712K	–	5755
2021 Q2	$712K	Sell	9,160 -7,987	-47%	-$606K	﹤0.01%	2911
2021 Q1	$1.28M	Buy	17,147 +15,698	+1,083%	+$1.45M	﹤0.01%	2335
2020 Q4	$247K	Buy	+1,449	New	+$215K	﹤0.01%	3630
2020 Q2	–	Sell	-1,979	Closed	-$269K	–	4794
2020 Q1	$194K	Sell	1,979 -23,032	-92%	-$2.63M	﹤0.01%	2878
2019 Q4	$3.23M	Sell	25,011 -9,272	-27%	-$936K	0.02%	838
2019 Q3	$2.58M	Buy	34,283 +32,415	+1,735%	+$3.83M	0.02%	1111
2019 Q2	$284K	Sell	1,868 -4,386	-70%	-$533K	﹤0.01%	2652
2019 Q1	$745K	Buy	+6,254	New	+$804K	﹤0.01%	2080

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PEAK6 Investments's SRPT Position: Q3 2023 in Review

PEAK6 Investments sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 5,094 shares — an estimated $576K sold.

PEAK6 Investments first reported a position in SRPT in Q1 2019 and held it in 10 quarters. The position peaked at $3.23M in Q4 2019. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

PEAK6 Investments reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 5,094 Sarepta Therapeutics shares in Q3 2023, an estimated $576K.
PEAK6 Investments first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 10 quarters.
PEAK6 Investments's Sarepta Therapeutics position peaked at $3.23M in Q4 2019.
394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.